Catalent Presentation: Toolbox For Ips Cell-Based Therapy: GMP iPSC Lines, Enhanced Gene Editing, New Protocols For MSC, Cardiac, As Well As RPE Induction, And Novel Feeder-Free NK Differentiation/Expansion Platform
Thursday, May 30, 2024 12:30 PM - 12:45 PM
Exhibit Hall - Theatre B
Global Showcase Presentation
Presenter
• Daniel Terheyden-Keighley, Scientist, Catalent Cell & Gene Therapies, Germany
• Boris Greber, Head of Research and Development, iPSC/CT, Catalent Cell & Gene Therapies, Germany
Cell therapy based on induced pluripotent stem cells (iPSCs) requires accessible GMP iPSC lines and robust manipulation procedures developed with a GMP mindset. Catalent will introduce a set of GMP-compliant iPS cell banks produced in a certified workflow. These lines of EU and US origin are available both as GMP and R&D stocks and have passed a stringent set of release criteria.
Using these lines, Catalent has systematically optimized gene knock-in efficiencies in iPSCs to above 30% (without selection) and also developed new GMP-friendly procedures for differentiation into critical cell types: mesenchymal stromal cells, cardiomyocytes, and retinal pigment epithelium.
Session Objectives:
• Learn new workflows solve shortcomings of previous approaches and will therefore present valuable platforms for cell replacement therapy and beyond.
• Learn new differentiation protocol forming hematopoietic precursor cells that may be cryopreserved and selectively be converted into various immune cell types.
• Daniel Terheyden-Keighley, Scientist, Catalent Cell & Gene Therapies, Germany
• Boris Greber, Head of Research and Development, iPSC/CT, Catalent Cell & Gene Therapies, Germany
Cell therapy based on induced pluripotent stem cells (iPSCs) requires accessible GMP iPSC lines and robust manipulation procedures developed with a GMP mindset. Catalent will introduce a set of GMP-compliant iPS cell banks produced in a certified workflow. These lines of EU and US origin are available both as GMP and R&D stocks and have passed a stringent set of release criteria.
Using these lines, Catalent has systematically optimized gene knock-in efficiencies in iPSCs to above 30% (without selection) and also developed new GMP-friendly procedures for differentiation into critical cell types: mesenchymal stromal cells, cardiomyocytes, and retinal pigment epithelium.
Session Objectives:
• Learn new workflows solve shortcomings of previous approaches and will therefore present valuable platforms for cell replacement therapy and beyond.
• Learn new differentiation protocol forming hematopoietic precursor cells that may be cryopreserved and selectively be converted into various immune cell types.
